BHVN.US Biohaven Ltd.

Healthcare Biotechnology USA Stocks
13.82 USD
Close of Nov 13, 2026
7.99 18.24
Market cap
USD 2.09B
P/E
-
P/B
203.79x
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is BHVN.US undervalued?

Graham number

The Graham number of Biohaven Ltd. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Biohaven Ltd. fundamental analysis

No fundamental analysis for Biohaven Ltd. yet.

Biohaven Ltd. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Biohaven Ltd.

Biohaven Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide. It develops BHV-1300, which is in Phase 2 clinical trial to treat Graves' disease and rheumatoid arthritis; BHV-1400 that is in Phase 2 clinical trial for treating IgA nephropathy; BHV-1600, which is in Phase 1 clinical trial for the treatment of peripartum cardiomyopathy; BHV-8000 that …

Full company profile